Food Elimination Diet Potential Alternative Treatment for EoE
June 9th 2023Investigators evaluated long-term outcomes among individuals who have eosinophilic esophagitis (EoE) and initiated first-line treatment with a food elimination diet after experiencing remission following stoppage of proton pump inhibitor monotherapy.
Read More
Axi-Cel Shows Favorable Safety, Efficacy in Real-World Study of Early FL Outcomes
June 9th 2023The autologous CAR T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated effectiveness and safety consistent with the ZUMA-5 trial when used in real-world settings to treat a broader population of patients with follicular lymphoma (FL).
Read More
Improving Access to Treatment Remains a Challenge in AML, Says Dr Jeffrey Lancet
June 9th 2023Much work is needed to address inequities and gaps in care access for patients with acute myeloid leukemia (AML), said Jeffrey Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center.
Watch
Experts Spar Over Role of Real-World Data as Replacement for Clinical Trials in Hematology
June 9th 2023A friendly debate held at the European Hematology Association 2023 Congress focused on the potential for real-world data to improve the generalizability of clinical trial results but also acknowledged the limitations and current challenges with these data.
Read More
Study Finds PSMA-PET May Hold Prognostic Utility in Prostate Cancer
June 9th 2023Research presented at the American Society of Clinical Oncology Annual Meeting found prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) to be associated with worse overall survival in prostate cancer without distant metastasis based on conventional imaging.
Read More
Dr Samyukta Mullangi: To Affect Prescribing Behavior, Payer Incentive Alignment Is Critical
June 9th 2023If payers can agree on consensus criteria to improve care quality or costs, that will help physicians remember and try to be compliant, said Samyukta Mullangi, MD, MBA, incoming medical director at Thyme Care.
Watch
Burgeoning Immunotherapy Options in Oncology Move Beyond CAR T and the Usual Disease States
June 9th 2023The use of immune therapies for hematological malignancies is expanding beyond chimeric antigen receptor (CAR) T-cell therapies in the traditional lymphoid disease states, but the impact on patient quality of life must remain top of mind, according to speakers at the European Hematology Association 2023 Congress.
Read More
Early CGM Initiation, Remote Data Review Decreased HbA1C in Youth With T1D: Dr David Maahs
June 8th 2023The pilot 4T study showed consistent hemoglobin A1C improvement in all children with type 1 diabetes (T1D) after 1 year, underscoring the importance of early continuous glucose monitoring (CGM) following diagnosis, explained David Maahs, MD, PhD, professor of pediatrics at Stanford University and division chief of pediatric endocrinology at Lucile Packard Children’s Hospital.
Watch
A Q&A With the NIEHS’ Dr Symielle Gaston: Understanding Racial/Ethnic Variations in Sleep Health
June 8th 2023In this interview with The American Journal of Managed Care®, Symielle A. Gaston, PhD, MPH, of the National Institute of Environmental Health Sciences (NIEHS) of the National Institutes of Health, explores the relationship between sleep health and outcomes disparities among patients of various races and ethnicities.
Read More
Mark Cuban’s Online Pharmacy Partners With Coherus Biosciences for Humira Biosimilar
June 8th 2023The Mark Cuban Cost Plus Drug Company, an online pharmacy dedicated to increasing access to lower-cost prescriptions, is partnering with Coherus Biosciences to distribute Yusimry, a biosimilar referencing Humira. It’s the first time the pharmacy has added a biosimilar to its list of drugs.
Read More
Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS
June 8th 2023Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome that is relapsed or refractory to erythropoiesis stimulating agents, according to findings from the phase 3 IMerge trial.
Read More
Dr Sheila Garland: CBT for Insomnia Improves Functioning in Patients With Cancer
June 7th 2023Targeting insomnia with cognitive behavior therapy is almost like a frontline therapy, because by doing so, you’re able to improve a whole host of other symptoms that would coexist with insomnia, explained Sheila Garland, PhD, MSc, Memorial University in Newfoundland, Canada.
Watch